BMG Pharma
BMG Pharma is an Italian pharmaceutical company that develops and licenses proprietary modified hyaluronic acid biomaterials (Hyaluromimethic® platform) through B2B partnerships with global pharmaceutical and cosmetic companies serving aesthetic, orthopedic, ophthalmic, dermatological, and oral care markets.
- Company typePrivate
- Founded2011
- HeadquartersMilan, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BMG Pharma does
BMG Pharma SpA is a privately-held Italian pharmaceutical and biotechnology company headquartered in Milan with a dedicated chemical plant and R&D center in Torviscosa, Friuli Venezia Giulia. The company develops and licenses biomaterials derived from modified hyaluronic acid (HA) using its proprietary Hyaluromimethic® technology platform, which performs covalent modification of HA at hydroxyl residues with functional, biologically active molecules. This produces a modular family of derivatives including Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Zinc-Gluconate combinations, each with distinct physicochemical properties tailored for specific applications. The company holds 140 patents across 9 patent families and 6 international brands, and operates four business units: BMG Biochemical (raw materials, recently spun off as an independent entity), BMG Bioaesthetic (Class III injectable aesthetic devices), BMG Therapeutics (Class III injectable orthopedic and ophthalmological devices including SGA400), and BMG Dermacare (professional cosmetic products under the HYALUVANCE® brand).
The business operates an asset-light B2B model combining raw materials supply, technology licensing, and co-development partnerships with international pharmaceutical and cosmetic companies. Production of finished products and clinical consultancy are outsourced to contract manufacturing organizations (CMOs), while marketing is conducted through international distribution partners. The customer base spans oral care (Dompè, Pierre Fabre, ISDIN, Polifarma, Bionativa, Sophos, Galen, Diomed Dermal), dermatology (Difa Cooper, Dr Gorkic), and aesthetic medicine, with finished products marketed under partner brands such as Euclorina, Elgydium, Bexident, Emoform, and GelX. The company's go-to-market combines enterprise field sales to pharma partners with direct engagement of health professionals (aesthetic doctors, nurses) for the HYALUVANCE® professional cosmetic line.
Current commercial focus is on scaling the Class III injectable pipeline (six dermal fillers and one orthopedic injectable in clinical/MDR regulatory stages in Europe), launching HYALUVANCE® Golden for aesthetic medicine mesotherapy, and licensing the Hyaluromimethic® platform to global pharmaceutical partners. The company is ISO 13485 certified and pursues European MDR registration through Notified Bodies TÜV and Eurofins. Revenue figures are not publicly disclosed, and the company remains privately held following minority investments from Massimo Doris (CEO of Banca Mediolanum, 2% stake acquired November 2022) and Friulia Finanziaria FVG (regional PE firm, ~$2.4M round in 2021).
BMG Pharma firmographics
Firmographics- Name
- BMG Pharma
- Legal name
- BMG Pharma SpA
- Website
- https://bmgpharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BMG Pharma is an Italian pharmaceutical company that develops and licenses proprietary modified hyaluronic acid biomaterials (Hyaluromimethic® platform) through B2B partnerships with global pharmaceutical and cosmetic companies serving aesthetic, orthopedic, ophthalmic, dermatological, and oral care markets.
- Ownership category
- akta.pro rank
BMG Pharma industry classification
Industry- Product category
- Biopharmaceuticals & Medical Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Medical & Food-Contact Specialty Compounds (IMANABAK)
Keywords
Where BMG Pharma is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
BMG Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Licensing/Property: Patents; ISO 13485 TUV Sud certification for medical devices; Know-how and technology licensing. Hyaluronic acid derivatives production plant; Marketing of raw materials through collaborations with international pharmaceutical companies.
- Aesthetic Applications Products: Licensing of aesthetic applications of injectable products based on hyaluronic acid butyrate derivatives (SHB) and lipoates (SHLF) with the international brand Hyaluromimethic®. 6 dermal fillers undergoing clinical trials and MDR registration in Europe.
- Orthopaedic Applications: Licensing of orthopaedic applications of injectable products based on hyaluronic acid lipoate derivative (SHLF). 1 injectable in preclinical investigation phase for MDR registration.
- Professional Cosmetics: Sale of cosmetics for professional use by aesthetic doctors with the international proprietary brand HYALUVANCE®. HYALUVANCE® GOLDEN available for marketing.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
BMG Pharma product offering
Product offeringCore offering
BMG Pharma develops, manufactures, and licenses innovative biomaterials based on its proprietary Hyaluromimethic® technology platform, which enables covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. The company produces hyaluronic acid derivative raw materials (SHB, SHL, SHLF, SHLFZ), Class III injectable medical devices (SGA400 for osteoarthritis; dermal fillers), and professional cosmetic products (HYALUVANCE® line for aesthetic medicine), serving global pharmaceutical partners and health professionals through licensing, contract manufacturing, and direct distribution.
Product overview
BMG Pharma is a pharmaceutical company with over 15 years of experience developing and partnering internationally on innovative medical products. The company has developed the proprietary Hyaluromimethic® technology platform for covalent modification of hyaluronic acid, which serves as the foundation for its product ecosystem. The portfolio includes four business units: BMG Biochemical (chemical technology hub producing functional ingredients and raw materials like SHB, SHL, SHLF derivatives), BMG Bioaesthetic (Class III injectable medical devices for aesthetic medicine), BMG Therapeutics (Class III injectable medical devices for orthopedics and ophthalmology, including SGA400), and BMG Dermacare (professional topical cosmetic products under the HYALUVANCE® brand including HYALUVANCE® Golden). The company also licenses its technology and holds 140 patents across 9 families globally.
Differentiator
Problem solved
Functional benefit
Brands
- HYALUVANCE®: International brand for professional cosmetic products for aesthetic medicine, including sterile topical products and the HYALUVANCE® GOLDEN line based on milk exosomes, type 3 collagen, and polynucleotides
- Hyaluromimethic®
- SGA400
- BMG Biochemical
- BMG Bioaesthetic
- BMG Therapeutics
- BMG Dermacare
Products and services
- Hyaluromimethic® Technology Platform Proprietary patented technology platform for covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. Licensed to pharmaceutical partners for the development of biomaterials, medical devices, and cosmetic products in aesthetic, orthopedic, ophthalmological, and dermatological applications.
- SGA400 Class 3 medical injectable based on Hyaluromimethic® technology for intraarticular therapy. Provides long intra-articular permanence, absorption of mechanical stress, modulation of inflammation and free radicals, and pain management for patients suffering from joint osteoarthritis.
- HYALUVANCE® Golden Sterile cosmetic vials (5x3ml) for professional use in aesthetic medicine. Based on milk exosomes, type 3 collagen, polynucleotides (PDRN), and high molecular weight hyaluronic acid. Indicated for skin rejuvenation mesotherapy treatments.
- HYALUVANCE® Professional Cosmetics Line International proprietary brand under which a new pipeline of professional cosmetic products for aesthetic medicine is being built. Includes sterile topical products distributed through BMG Dermacare for medical professionals offering innovative aesthetic treatments.
- Hyaluronic Acid Derivative Raw Materials (SHB, SHL, SHLF, SHLFZ) Functional hyaluronic acid derivative raw materials produced by BMG Biochemical and supplied to pharmaceutical partners. Includes Sodium Hyaluronate Butyrate (SHB), Sodium Hyaluronate Lipoate (SHL), Sodium Hyaluronate Lipoate Formate (SHLF), and Sodium Hyaluronate Lipoate Formate and Zinc Gluconate (SHLFZ) — each with distinct functional properties for dermatology, tissue repair, aesthetic, and medical applications.
- Hyaluromimethic® Dermal Fillers Pipeline (6 products in clinical trials/MDR registration) Licensed aesthetic application injectable products based on Hyaluromimethic® hyaluronic acid derivatives (SHB and SHLF). Six dermal fillers currently in clinical trials and MDR registration in Europe for aesthetic dermatology and biorevitalization applications.
Quantifiable outcome
- 4 new patents created and 36 innovative products registered, 37 launched internationally in two years
- +1 more outcomes
Companies that use BMG Pharma
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles3 records
BMG Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
BMG Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Allianz PowerVolley MilanominorBMG Pharma has always supported Allianz PowerVolley Milano volleyball team. The team won the 2026 CEV Challenge Cup. The company aims to bring prominent volleyball back to Milan.
- HTL BiotechnologycoreBMG Pharma and HTL Biotechnology signed an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic® technology. This partnership ensures production capability for the exclusive technology platform.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
BMG Pharma competitors and assessment
Company assessmentEmerging players
- Dompé Farmaceutici: Italian pharma with a board connection to BMG and a disclosed BMG customer using its ingredients in oral-care ranges. Comparable as a like-for-like Italian specialty pharma and existing commercial partner for BMG's technology.
- Revance Therapeutics: US aesthetics-focused biotech whose portfolio includes the RHA Collection of hyaluronic acid fillers following the Teoxane US acquisition. Comparable business model — innovator aesthetics platform leveraging differentiated HA technology — to BMG Bioaesthetic.
Broad incumbents
- Galderma: Global dermatology and aesthetic medicine leader selling hyaluronic-acid-based dermal fillers (Restylane, Emervel) and prescription aesthetics. Directly comparable to BMG Bioaesthetic and HYALUVANCE® as the incumbent BMG is trying to disrupt in fillers and professional aesthetic skincare.
- Merz Aesthetics: Subsidiary of Merz Pharma marketing hyaluronic acid fillers (Belotero), biostimulators and medical skincare. Competes head-on with BMG Bioaesthetic and HYALUVANCE® in clinic-administered aesthetics.
Direct peers
- Fidia Farmaceutici: Italian specialty pharma whose hyaluronic acid-based products (e.g. Hyalgan, Hymovis) cover intra-articular osteoarthritis therapy and aesthetic medicine. Direct category overlap with BMG Therapeutics' SGA400 and the BMG Bioaesthetic injectable line.
- Sinclair Pharma: Aesthetic medicine company previously LSE-listed, founded by BMG's current CEO Marco Mastrodonato. Sells hyaluronic-acid dermal fillers and collagen-stimulating injectables (e.g. Ellansé, MaiLi). Same hyaluronic-acid-based injectable franchise, same end customer (aesthetic physicians), making it the closest direct comparable.
- Teoxane Laboratories: Swiss manufacturer of hyaluronic acid-based dermal fillers (Teosyal RHA range) and professional cosmeceuticals. Overlaps with BMG Bioaesthetic's injectable pipeline and HYALUVANCE® professional skincare in the same clinician-administered channel.
- Anika Therapeutics: US-based developer of hyaluronic acid-based intra-articular and regenerative products (e.g. Monovisc, Orthovisc, Cingal) for osteoarthritis and tendon repair, plus aesthetic HA offerings. The cleanest US analog to BMG Therapeutics' SGA400 program.
- IBSA Farmaceutici: Italian private pharma company with a substantial hyaluronic acid portfolio including intra-articular injectables for osteoarthritis and aesthetic dermatology products. Closely comparable to BMG Therapeutics (SGA400 osteoarthritis injectable) and BMG Bioaesthetic.
Others
- HTL Biotechnology: French-Japanese specialist manufacturer of high-purity hyaluronic acid for medical and aesthetic applications. Signed a 2022 production agreement with BMG, making it a critical supplier/partner rather than a competitor, but a highly relevant comparable for understanding HA ingredient economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BMG Pharma social profiles
Digital presenceBMG Pharma compliance and trust
Trust signalCompliance2 records
BMG Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
BMG Pharma leadership team
Management profileNumber of profiles
Profiles7 records
BMG Pharma subsidiaries and ownership
Company hierarchySubsidiaries4 records
BMG Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BMG Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BMG Pharma
What does BMG Pharma do?
BMG Pharma develops, manufactures, and licenses innovative biomaterials based on its proprietary Hyaluromimethic® technology platform, which enables covalent modification of hyaluronic acid at hydroxyl residues with functional, biologically active molecules. The company produces hyaluronic acid derivative raw materials (SHB, SHL, SHLF, SHLFZ), Class III injectable medical devices (SGA400 for osteoarthritis; dermal fillers), and professional cosmetic products (HYALUVANCE® line for aesthetic medicine), serving global pharmaceutical partners and health professionals through licensing, contract manufacturing, and direct distribution.
Is BMG Pharma a public or private company?
BMG Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BMG Pharma founded?
BMG Pharma was founded in 2011. It employs 11 to 50 people.
Where is BMG Pharma based?
BMG Pharma is headquartered in Milan, Italy, in the Europe region.
How does BMG Pharma make money?
Four revenue lines are on record. Licensing/Property is the primary driver. The others are aesthetic Applications Products, orthopaedic Applications and professional Cosmetics.
Who are BMG Pharma's main competitors?
Emerging players on record are Dompé Farmaceutici and Revance Therapeutics. Broad incumbents are Galderma and Merz Aesthetics. Direct peers are Fidia Farmaceutici, Sinclair Pharma, Teoxane Laboratories, Anika Therapeutics and IBSA Farmaceutici. HTL Biotechnology is listed as an others.
Does BMG Pharma have an API?
No public API is recorded for BMG Pharma.
What industry is BMG Pharma in?
BMG Pharma's product category is Biopharmaceuticals & Medical Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.